How to handle the delayed or missed dose of rivaroxaban in patients with non-valvular atrial fibrillation: model-informed remedial dosing

References

• Misselwitz F, Berkowitz SD, Perzborn E. The discovery and development of rivaroxaban. Ann N Y Acad Sci. 2011;1222(1):64–75.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. XARELTO® [insert package] [Cited Jan 31, 2021]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202439s031,022406s035lbl.pdf
   Google Scholar
• Zhu J, Alexander GC, Nazarian S, et al. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017. Pharmacotherapy. 2018;38(9):907–920.
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Dondi L, Andreotti F, et al. Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people. Am Heart J. 2020;220:12–19.
   PubMed Web of Science ®Google Scholar
• Ingrasciotta Y, Crisafulli S, Pizzimenti V, et al. Pharmacokinetics of new oral anticoagulants: implications for use in routine care. Expert Opin Drug Metab Toxicol. 2018;14(10):1057–1069.
   PubMed Web of Science ®Google Scholar
• Mueck W, Stampfuss J, Kubitza D, et al. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1–16.
   PubMed Web of Science ®Google Scholar
• Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387–2394.
   PubMed Web of Science ®Google Scholar
• Pham PN, Brown JD. Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter? BMC Cardiovasc Disord. 2019;19(1):64.
   PubMed Web of Science ®Google Scholar
• Kim D, Yang P-S, Jang E, et al. 10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population. Am Heart J. 2018;202:20–26.
   PubMed Web of Science ®Google Scholar
• Weber C, Hung J, Hickling S, et al. Drivers of hospitalisation trends for non-valvular atrial fibrillation in Western Australia, 2000–2013. Int J Cardiol. 2019;276:273–277.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bernal CL, Peiró S, Hurtado I, et al. Primary Nonadherence to Oral Anticoagulants in Patients with Atrial Fibrillation: real-World Data from a Population-Based Cohort. J Manag Care Spec Pharm. 2018;24(5):440–448.
   PubMed Web of Science ®Google Scholar
• Reading SR, Black MH, Singer DE, et al. Risk factors for medication non-adherence among atrial fibrillation patients. BMC Cardiovasc Disord. 2019;19(1):38.
   PubMed Web of Science ®Google Scholar
• Moll S, Berkowitz JN, Miars CW. Elite athletes and anticoagulant therapy: an intermittent dosing strategy. Hematology Am Soc Hematol Educ Program. 2018;(1):412–417.
   PubMed Web of Science ®Google Scholar
• Deshpande CG, Kogut S, Laforge R, et al. Impact of medication adherence on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants. Curr Med Res Opin. 2018;34(7):1285–1292.
   PubMed Web of Science ®Google Scholar
• Yao X, Abraham NS, Alexander GC, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc. 2016;5(2):e003074.
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium. Xarelto 20/15mg film-coated tablets [Package leaflet: information for the user] [Cited Jan 31, 2021]. Available from: https://www.medicines.org.uk/emc/files/pil.2793.pdf
   Google Scholar
• New Zealand Medicines and Medical Devices Safety Authority. XARELTO®[Consumer Medicine Information] [Cited Jan 31, 2021]. Available from: https://www.medsafe.govt.nz/Consumers/CMI/x/Xarelto.pdf
   Google Scholar
• Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393.
   PubMed Web of Science ®Google Scholar
• Wu J-Y, Yu G, Li G-F. Model-Informed Approaches for Alternative Aripiprazole Dosing Regimens and Missed Dose Management: towards Better Adherence to Antipsychotic Pharmacotherapy. Eur J Drug Metab Pharmacokinet. 2018;43(4):471–473.
   PubMed Web of Science ®Google Scholar
• Hughes DA. Medication adherence—Key considerations for clinical pharmacologists. Br J Clin Pharmacol. 2020;86(4):628–629.
   PubMed Web of Science ®Google Scholar
• Wang C-Y, Jiao Z, Ding J-J, et al. Remedial dosing recommendations for delayed or missed doses of valproic acid in patients with epilepsy based on Monte Carlo simulations. Epilepsy Behav. 2020;111:107265.
   PubMed Web of Science ®Google Scholar
• Yu E-Q, Jiao Z, Wang C-Y, et al. Remedial dosing recommendations for delayed or missed doses of lamotrigine in pediatric patients with epilepsy using Monte Carlo simulations. Epilepsy Behav. 2019;96:132–140.
   PubMed Web of Science ®Google Scholar
• Ding J-J, Zhang Y-J, Jiao Z, et al. The effect of poor compliance on the pharmacokinetics of carbamazepine and its epoxide metabolite using Monte Carlo simulation. Acta Pharmacol Sin. 2012;33(11):1431–1440.
   PubMed Web of Science ®Google Scholar
• Van Dijkman SC, Rauwe WM, Danhof M, et al. Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children. Br J Clin Pharmacol. 2018;84(1):97–111.
   PubMed Web of Science ®Google Scholar
• Samtani MN, Sheehan JJ, Fu D-J, et al. Management of antipsychotic treatment discontinuation and interruptions using model-based simulations. Clinical Pharmacology : Advances and Applications. 2012;4:25–40.
   PubMedGoogle Scholar
• Magnusson MO, Samtani MN, Plan EL, et al. Dosing and switching strategies for paliperidone palmitate 3-month formulation in patients with schizophrenia based on population pharmacokinetic modeling and simulation, and clinical trial data. CNS Drugs. 2017;31(4):273–288.
   PubMed Web of Science ®Google Scholar
• Hard ML, Wehr AY, Sadler BM, et al. Population pharmacokinetic analysis and model-based simulations of aripiprazole for a 1-day initiation regimen for the long-acting antipsychotic aripiprazole lauroxil. Eur J Drug Metab Pharmacokinet. 2018;43(4):461–469.
   PubMed Web of Science ®Google Scholar
• Saint-Marcoux F, Woillard J-B, Monchaud C, et al. How to handle missed or delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic investigation. Pharmacol Res. 2015;100:281–287.
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Ulrichsen SP, Pedersen L, et al. 30-year nationwide trends in incidence of atrial fibrillation in Denmark and associated 5-year risk of heart failure, stroke, and death. Int J Cardiol. 2016;225:30–36.
   PubMed Web of Science ®Google Scholar
• Girgis IG, Patel MR, Peters GR, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. J Clin Pharmacol. 2014;54(8):917–927.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Gu J-Q, Guo Y-P, Jiao Z, et al. How to handle delayed or missed doses: a population pharmacokinetic perspective. Eur J Drug Metab Pharmacokinet. 2020;45(2):163–172.
   PubMed Web of Science ®Google Scholar
• Albassam A, Hughes DA. What should patients do if they miss a dose? A systematic review of patient information leaflets and summaries of product characteristics. Eur J Clin Pharmacol. 2021;77(2):251–260.
   PubMed Web of Science ®Google Scholar
• Cuker A, Siegal D. Monitoring and reversal of direct oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2015;2015(1):117–124.
   PubMed Web of Science ®Google Scholar
• Samuelson BT, Cuker A. Measurement and reversal of the direct oral anticoagulants. Blood Rev. 2017;31(1):77–84.
   PubMed Web of Science ®Google Scholar
• Samuelson BT, Cuker A, Siegal DM, et al. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest. 2017;151(1):127–138.
   PubMed Web of Science ®Google Scholar
• Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2Suppl):e44S–e88S.
   PubMed Web of Science ®Google Scholar
• Baglin T, Hillarp A, Tripodi A, et al. Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11(4):756–760.
   Google Scholar
• Zhang X-Y, Trame MN, Lesko LJ, et al. Sobol sensitivity analysis: a tool to guide the development and evaluation of systems pharmacology models. CPT Pharmacometrics Syst Pharmacol. 2015;4(2):69–79. .
   PubMedGoogle Scholar
• Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry. 1978;17(8):1371–1377.
   PubMed Web of Science ®Google Scholar
• Sakaguchi T, Osanai H, Murase Y, et al. Monitoring of anti-Xa activity and factors related to bleeding events: a study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban. J Cardiol. 2017;70(3):244–249.
   PubMed Web of Science ®Google Scholar
• Wada S, Toyoda K, Sato S, et al. Anti-Xa activity and event risk in patients with direct factor Xa inhibitors initiated early after stroke. Circ J. 2018;82(11):2872–2879.
   PubMed Web of Science ®Google Scholar
• Nakano Y, Kondo T, Osanai H, et al. Clinical usefulness of measuring prothrombin time and soluble fibrin levels in Japanese patients with atrial fibrillation receiving rivaroxaban. J Cardiol. 2015;65(3):185–190.
   PubMed Web of Science ®Google Scholar
• Hirota N, Suzuki S, Yamasaki M, et al. Analysis of bioMARKer Distribution and Individual Reproducibility Under Rivaroxaban Treatment in Japanese Patients with Non-Valvular Atrial Fibrillation (R-MARK Study, CVI ARO2). Int Heart J. 2020;61(4):695–704.
   PubMed Web of Science ®Google Scholar
• Martin AC, Thomas W, Mahir Z, et al. Direct oral anticoagulant concentrations in obese and high body weight patients: a cohort study. Thromb Haemost. 2021;121(2):224–233.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Quinlan DJ, Hirsh J, et al. Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation. JAMA Cardiol. 2017;2(5):566–574.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yan X, Fox KAA, et al. Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. J Thromb Thrombolysis. 2020;50(1):20–29.
   PubMed Web of Science ®Google Scholar
• Gragnano F, Calabro P, Valgimigli M. Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention? Eur Heart J. 2019;40(2):216–217.
   PubMed Web of Science ®Google Scholar
• Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019;40(31):2632–2653.
   PubMed Web of Science ®Google Scholar
• Corpataux N, Spirito A, Gragnano F, et al. Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. Eur Heart J. 2020;41(38):3743–3749.
   PubMed Web of Science ®Google Scholar